WallStreetZenWallStreetZen

NASDAQ: APGE
Apogee Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for APGE

Based on 4 analysts offering 12 month price targets for Apogee Therapeutics Inc

Min Forecast
$89.00+168.8%
Avg Forecast
$96.00+189.94%
Max Forecast
$110.00+232.23%

Should I buy or sell APGE stock?

Based on 4 analysts offering ratings for Apogee Therapeutics Inc.

Strong Buy
Strong Buy
3 analysts 75%
Buy
1 analysts 25%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although APGE's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates APGE as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -8.02% per year. Learn More

Be the first to know when Wall Street analysts revise their APGE stock forecasts and price targets.

APGE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-13
lockedlocked$00.00+00.00%2024-12-03
lockedlocked$00.00+00.00%2024-12-02
lockedlocked$00.00+00.00%2024-11-25

1 of 1

Forecast return on equity

Is APGE forecast to generate an efficient return?

Company
-45.62%
Industry
147.61%
Market
81.77%
APGE's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is APGE forecast to generate an efficient return on assets?

Company
-43.37%
Industry
35.5%
APGE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

APGE earnings per share forecast

What is APGE's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$4.53
Avg 2 year Forecast
-$5.19
Avg 3 year Forecast
-$5.09

APGE revenue forecast

What is APGE's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$137.0M
Avg 2 year Forecast
$243.0M
Avg 3 year Forecast
$1.0B

APGE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
APGE$33.11$96.00+189.94%Strong Buy
LGND$104.97$147.50+40.52%Strong Buy
MIRM$39.10$67.25+71.99%Strong Buy
FOLD$6.83$17.17+151.35%Strong Buy
TARS$49.25$63.67+29.27%Strong Buy
View Top Biotech Stocks

Apogee Therapeutics Stock Forecast FAQ

Is Apogee Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: APGE) stock is to Strong Buy APGE stock.

Out of 4 analysts, 3 (75%) are recommending APGE as a Strong Buy, 1 (25%) are recommending APGE as a Buy, 0 (0%) are recommending APGE as a Hold, 0 (0%) are recommending APGE as a Sell, and 0 (0%) are recommending APGE as a Strong Sell.

If you're new to stock investing, here's how to buy Apogee Therapeutics stock.

What is APGE's earnings growth forecast for 2025-2027?

(NASDAQ: APGE) Apogee Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.37%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.31%.

Apogee Therapeutics's earnings in 2025 is -$182,146,000.On average, 5 Wall Street analysts forecast APGE's earnings for 2025 to be -$269,787,436, with the lowest APGE earnings forecast at -$302,276,175, and the highest APGE earnings forecast at -$208,856,176. On average, 4 Wall Street analysts forecast APGE's earnings for 2026 to be -$308,821,525, with the lowest APGE earnings forecast at -$354,638,977, and the highest APGE earnings forecast at -$257,648,787.

In 2027, APGE is forecast to generate -$302,871,207 in earnings, with the lowest earnings forecast at -$330,837,703 and the highest earnings forecast at -$274,904,710.

What is APGE's revenue growth forecast for 2028-2030?

(NASDAQ: APGE) Apogee Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.42%.

Apogee Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast APGE's revenue for 2028 to be $8,151,936,208, with the lowest APGE revenue forecast at $8,151,936,208, and the highest APGE revenue forecast at $8,151,936,208. On average, 2 Wall Street analysts forecast APGE's revenue for 2029 to be $14,461,951,355, with the lowest APGE revenue forecast at $6,074,680,055, and the highest APGE revenue forecast at $22,849,222,656.

In 2030, APGE is forecast to generate $59,830,749,028 in revenue, with the lowest revenue forecast at $39,093,591,888 and the highest revenue forecast at $80,567,906,168.

What is APGE's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: APGE) forecast ROA is -43.37%, which is lower than the forecast US Biotechnology industry average of 35.5%.

What is APGE's Price Target?

According to 4 Wall Street analysts that have issued a 1 year APGE price target, the average APGE price target is $96.00, with the highest APGE stock price forecast at $110.00 and the lowest APGE stock price forecast at $89.00.

On average, Wall Street analysts predict that Apogee Therapeutics's share price could reach $96.00 by Mar 13, 2026. The average Apogee Therapeutics stock price prediction forecasts a potential upside of 189.94% from the current APGE share price of $33.11.

What is APGE's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: APGE) Apogee Therapeutics's current Earnings Per Share (EPS) is -$3.30. On average, analysts forecast that APGE's EPS will be -$4.53 for 2025, with the lowest EPS forecast at -$5.08, and the highest EPS forecast at -$3.51. On average, analysts forecast that APGE's EPS will be -$5.19 for 2026, with the lowest EPS forecast at -$5.96, and the highest EPS forecast at -$4.33. In 2027, APGE's EPS is forecast to hit -$5.09 (min: -$5.56, max: -$4.62).

What is APGE's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: APGE) forecast ROE is -45.62%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.